Faculty Profile: J. Dawn Abbott, MD

J. Dawn Abbott
J. Dawn Abbott, MD
Associate Professor of Medicine
Medicine
Work: +1 401-444-8540

Biography

J. Dawn Abbott, M.D., is the Director of the Interventional Cardiology Fellowship Training Program at Brown and an interventional cardiologist at Rhode Island Hospital. Her clinical research focuses on percutaneous coronary intervention and peripheral arterial disease. She is a Co-Investigator on the NIH-Sponsored MINT Trial, a grant that is funding a pilot trial to evaluate the role of transfusion therapy in patients with symptomatic coronary artery disease. She is the Site-Principal Investigator at Rhode Island Hospital for several NIH funded studies (Dynamic Registry of Percutaneous Coronary Intervention, PACE-MI, BARI 2D) as well as multicenter investigator initiated and industry funded trials. She has examined the importance of several factors such as stent selection (drug-eluting versus bare metal), gender, and antiplatelet therapy on outcomes in percutaneous intervention. Current actively enrolling trials include the SAFE-PCI trial examining radial versus femoral access for coronary intervention in women, the RIVER-PCI trial assessing the use of the antianginal drug ranolazine in patients with incomplete revascularization, and the renalguard study examining prevention of contrast induced nephropathy by forced diuresis.

Institutions

RIH

Affiliations

Fellow of the American College of Cardiology
American Heart Association, Member of the Council on Cardiovascular Radiology and Intervention
Fellow of the Society of Coronary Angiography and Interventions

Funded Research

American College of Cardiology Foundation (ACCF) Career Development Award in Acute Coronary Syndromes (07/05-06/06)

The Rhode Island Foundation: Medical Research Grant Award (2/07-1/08)

1RC2HL101458-01 NIH/NHLBI, Carson (PI), 2009-2011. Application Title: Transfusion Trigger Trial in Coronary Artery Disease: A Pilot Study. Project Period: 9/30/2009 – 9/29/2011. Role: Co-investigator

Selected Publications

  • Abbott JD. Opportunity for improvement: use of intravascular ultrasound in stent thrombosis. Cath Cardiovasc Interv in press 2013. (2013)
  • Mulukutla SR, Abbott JD et al. Benefit of Long-Term Dual Anti-Platelet Therapy in Patients Treated with Drug-Eluting Stents: From the NHLBI Dynamic Registry American Journal of Cardiology 2013;111:486-492. (2013)
  • Abbott JD and Madiraju S. Drug Eluting Stent Neointimal Regression: A Welcomed Change. Cath Cardiovasc Interv 2013; 81:283-4. (2013)
  • Prahbakar S and Abbott JD. Factors Influencing the Outcomes of Percutaneous Coronary Intervention in the Stent Era. Interventional Cardiology 2012; 4(5) 557-568. (2012)
  • Truesdell AT and Abbott JD. Bioresorbable Polymers: A Temporary Solution? Cath Cardiovasc Interv 2012;80:797–798. (2012)
  • Abbott JD. More than Addition: The Use of Fractional Flow Reserve in Serial Stenosis. JACC Cardiovasc Intv 2012;5:1019-1020. (2012)
  • Truesdell A, Li J, Delgado GA, Abbott JD, Atalay MK, Singh AK. Challenges in the Management of Postpartum Spontaneous Coronary Artery Dissection: An Illustrative Case Series and Review of the Literature. Interventional Cardiology. 2012;4:371-386 (2012)
  • Abbott, JD. Lessons Learned from Recent Randomized Clinical Trials for Intermittent Claudication. Circ Cardiovasc Interv 2012;5:139-141. (2012)
  • Spence N, Muratori J, Reinert S, Sharaf BL, and Abbott JD. Sex Differences in Door to Electrocardiogram and Balloon Times in Patients with ST segment Elevation Myocardial Infarction. Medicine Health RI 2012; 95(11) 340-341 (2012)
  • Vasaiwala S, Vlachos H, Selzer F, Marroquin O., Mulukutla S, Abbott JD, and Williams DO. Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry) Am J Cardiol 2012;(110)8:1113-8. (2012)
  • Abbott JD, Lombardero MS, Barsness GW, Pena-Sing I, Buitron L, Singh P, Woodhead G, Tardif JC, Kelsey SF and the BARI 2D Investigators. Ankle-Brachial Index and Cardiovascular Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Am Heart J 2012 Vol. 164, Issue 4, Pages 585-590. (2012)
  • Leitner J, Vlachos HA, Selzer F, Jamal SM, Kip KE, Williams DO, Abbott JD. Outcomes of Drug-Eluting Stents for Protected Left Main Coronary Artery Disease (From the Multicenter, United States DEScover Registry) Am J Cardiol 2012;109:466–470. (2012)
  • Abbott JD, Earl T, Vlachos HE, Selzer F, Vaidya KA, Romero A, Kip KE, Williams DO. Direct Stenting Compared to Balloon Pre-dilation in Drug Eluting Stents: 1-Year Outcomes from the DEScover Registry. Catheterization and Cardiovascular Interventions 2012 79:84–89 (2012)
  • Muradi HA, Mehra A, Okolo J, Vlachos H, Selzer F, Marroquin OC, MD; Skelding K, Holper EM, Williams DO, Abbott JD. Clinical Presentation and Predictors of Target Vessel Revascularization after Drug-Eluting Stent Implantation Cardiovascular revascularization Medicine 2012; 13(6) 311-315. (2012)